Biocept Inc (BIOC) was Initiated by ROTH Capital to “Buy” and the brokerage firm has set the Price Target at $1.20. ROTH Capital advised their investors in a research report released on Jun 6, 2016.
Biocept Inc closed down -0.009 points or -1.45% at $0.61 with 3,39,914 shares getting traded on Friday. Post opening the session at $0.62, the shares hit an intraday low of $0.56 and an intraday high of $0.63 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on May 5, 2016, Edward A. Neff (director) purchased 100,000 shares at $1.00 per share price. According to the SEC, on May 5, 2016, David F Hale (director) purchased 50,000 shares at $1.00 per share price. On May 5, 2016, Bruce Gerhardt (director) purchased 25,000 shares at $1.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Biocept Inc. is a cancer diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) tests utilizing a standard blood sample. Its marketed tests are OncoCEE-BR for breast cancer CTC enumeration and analysis OncoCEE-GA for gastric cancer CTC enumeration and analysis and OncoCEE-LU for non-small cell lung cancer or NSCLC CTC enumeration and analysis. Its marketed test and the tests under development for the enumeration and analysis of CTCs utilize its Cell Enrichment and Extraction or CEE technology and the tests under development for the detection and analysis of ctDNA utilize the Company’s CEE-Selector technology each performed on a standard blood sample. The CEE technology is an internally developed microfluidics-based CTC capture and analysis platform with enabling features that change how CTC testing can be used by clinicians by providing real-time biomarker monitoring with a standard blood sample.